Oncothyreon

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

[Read More]

Oncothyreon acquires Alpine Biosciences

Wednesday, August 13, 2014

Oncothyreon, a Washington-based biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, has acquired Alpine Biosciences, a Seattle, Wash.-based privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. 

[Read More]

Merck to continue development of Tecemotide in phase III trial

Tuesday, October 1, 2013

Merck Serono, the biopharmaceutical division of Merck, has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide  (also known as L-BLP25 and formerly known as Stimuvax). Merck Serono, which is developing tecemotide under a license agreement with Oncothyreon, will conduct a new phase III trial called START2 for patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

[Read More]

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

[Read More]

Mymetics ropes in Dendreon vets

Wednesday, April 11, 2012

Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.

[Read More]

Oncothyreon advances to phase II of PX-866 trial

Thursday, October 20, 2011

Oncothyreon it has initiated the phase II portion of  its ongoing phase I/II trial of PX-866 in combination with the chemotherapeutic agent  docetaxel (Taxotere) following successful completion of the phase I dose escalation portion  of the study. PX-866 is a small molecule compound designed to inhibit  the activity of phosphatidylinositol-3-kinase (PI-3K), a component of  an important cell survival signaling pathway.

[Read More]